ABIVAX SA EO -,01

ABIVAX SA EO -,01

Share · FR0012333284 · A14UQC (XPAR)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of ABIVAX SA EO -,01
No Price
Closing Price XPAR 28.04.2026: 95,60 EUR
28.04.2026 15:24
Current Prices from ABIVAX SA EO -,01
ExchangeTickerCurrencyLast TradePriceDaily Change
XPAR: Paris
Paris
ABVX.PA
EUR
28.04.2026 15:24
95,60 EUR
0,35 EUR
+0,37 %
XLON: London
London
0RA9.L
EUR
28.04.2026 15:08
95,55 EUR
0,30 EUR
+0,31 %
XDQU: Quotrix
Quotrix
ASAAPE84.DUSD
EUR
28.04.2026 05:27
95,90 EUR
-0,10 EUR
-0,10 %
OTC: UTC
UTC
AAVXF
USD
27.04.2026 13:30
115,65 USD
-
XDUS: Düsseldorf
Düsseldorf
ASAAPE84.DUSB
EUR
27.04.2026 06:10
98,05 EUR
-
XHAM: Hamburg
Hamburg
ASAAPE84.HAMB
EUR
23.04.2026 06:12
100,00 EUR
-
Share Float & Liquidity
Free Float 80,89 %
Shares Float 64,14 M
Shares Outstanding 79,29 M
Company Profile for ABIVAX SA EO -,01 Share
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

Company Data

Name ABIVAX SA EO -,01
Company Abivax S.A.
Website https://www.abivax.com
Primary Exchange XPAR Paris
WKN A14UQC
ISIN FR0012333284
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Marc M. P. de Garidel
Market Capitalization 9 Mrd.
Country France
Currency EUR
Employees 0,1 T
Address 5, rue de la Baume, 75008 Paris
IPO Date 2015-06-26

Ticker Symbols

Name Symbol
Over The Counter AAVXF
Düsseldorf ASAAPE84.DUSB
Frankfurt 2X1.F
Hamburg ASAAPE84.HAMB
London 0RA9.L
Paris ABVX.PA
Quotrix ASAAPE84.DUSD
XETRA 2X1.DE
More Shares
Investors who hold ABIVAX SA EO -,01 also have the following shares in their portfolio:
Hokuto Corporation
Hokuto Corporation Share
SAPPI PAPIER 21/28 REGS
SAPPI PAPIER 21/28 REGS Bond